Advarra Survey Finds Increased Burden on Clinical Trial Sites
Two-thirds of respondents believe setup and training on trial sponsor technology are more problematic than five years ago.
Advarra revealed findings from its 2023 Study Activation Survey indicating increases in site burden since 2018. According to the report, around 60% of sites say their study volume is higher plus they are managing more sponsor-provided technology, which was rated a higher burden than contracting and budgeting. Furthermore, 55% of sites report setup and training on sponsor technology to be extremely or very burdensome, and 67% say it's gotten worse in the past five years.
"Sites are increasingly saddled with complex technologies and duplicative, administrative tasks.We need to come together as an industry and support both sites and sponsors with technology that works for each stakeholder respectively and helps improve clinical research – not hinder it," said Gadi Saarony, CEO, Advarra."Advarra uniquely knows and understands the needs of sponsors, CROs, sites, and participants and is committed to driving industrywide stakeholder collaboration and to be the pioneer in connecting the clinical research ecosystem."
Reference: New Clinical Trial Industry Survey Reveals Increased Burdens on Sites. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/new-clinical-trial-industry-survey-reveals-increased-burdens-on-sites-301958244.html
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
